Arthritis, Rheumatoid

Immunology
64
Pipeline Programs
22
Companies
50
Clinical Trials
10
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
6
2
21
1
19
15
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
873%
Small Molecule
327%
+ 63 programs with unclassified modality

On Market (10)

Approved therapies currently available

Roche
ACTEMRAApproved
tocilizumab
Roche
Interleukin-6 Receptor Antagonist [EPC]intravenous, subcutaneous2013
U
ANJESOApproved
meloxicam
Unknown Company
intravenous2020
Sanofi
ARAVAApproved
leflunomide
Sanofi
Antirheumatic Agent [EPC]oral1998
Pfizer
BEXTRAApproved
valdecoxib
Pfizer
oral2001
U
LEFLUNOMIDEApproved
leflunomide
Unknown Company
Antirheumatic Agent [EPC]oral2019
U
MELOXICAMApproved
meloxicam
Unknown Company
oral2006
Boehringer Ingelheim
MOBICApproved
meloxicam
Boehringer Ingelheim
oral2000
U
RAMIPRILApproved
ramipril
Unknown Company
Angiotensin Converting Enzyme Inhibitor [EPC]oral2008
U
VIVLODEXApproved
meloxicam
Unknown Company
oral2015
U
VOSTALLYApproved
ramipril
Unknown Company
Angiotensin Converting Enzyme Inhibitor [EPC]oral2025

Competitive Landscape

21 companies ranked by most advanced pipeline stage

Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
16 programs
1
4
6
1
BI 695500Phase 31 trial
BI 695500Phase 31 trial
BI 695501Phase 31 trial
BI 695501Phase 31 trial
MeloxicamPhase 31 trial
+11 more programs
Active Trials
NCT05855109Completed1,304Est. Jun 2025
NCT02184065Completed22,639
NCT02184052Completed121
+13 more trials
Pfizer
PfizerNEW YORK, NY
8 programs
1
2
1
valdecoxibPhase 4Small Molecule1 trial
MaravirocPhase 21 trial
TRU-015Phase 21 trial
PLA-695Phase 11 trial
Comparative Analysis of Outcomes Among Patients Treated With Xeljanz vs BiologicsN/A1 trial
+3 more programs
Active Trials
NCT03964649Completed7,308Est. Apr 2020
NCT04428424Completed1,493Est. Aug 2020
NCT04428411Completed486Est. Aug 2020
+9 more trials
Sanofi
SanofiPARIS, France
3 programs
1
2
LEFLUNOMIDEPhase 41 trial
LeflunomidePhase 41 trial
RamiprilPhase 2/3Small Molecule1 trial
Active Trials
NCT00273533Completed13Est. Jul 2006
NCT00451971Completed249
NCT00280644Completed60
Abbott
AbbottABBOTT PARK, IL
2 programs
1
adalimumabPhase 4Monoclonal Antibody
adalimumabN/AMonoclonal Antibody1 trial
Active Trials
NCT01197144Completed70Est. Nov 2016
Roche
RocheSTAVANGER NORWAY, Norway
1 program
1
TocilizumabPhase 4Monoclonal Antibody1 trial
Active Trials
NCT02087696Unknown122Est. Jul 2016
GSK
GSKLONDON, United Kingdom
16 programs
4
7
2
GW406381Phase 31 trial
OtilimabPhase 3Monoclonal Antibody
GW274150Phase 21 trial
GW856553Phase 21 trial
GW856553Phase 21 trial
+11 more programs
Active Trials
NCT00330889Completed32Est. Dec 2006
NCT01750931Completed28Est. Oct 2013
NCT03285191Completed30Est. Aug 2017
+12 more trials
M&
Merck & Co.RAHWAY, NJ
6 programs
1
2
Infliximab + methotrexatePhase 31 trial
SC golimumabPhase 3Monoclonal Antibody1 trial
MK0782Phase 22 trials
Hanyang University Medical Center Arthritis NetworkN/A1 trial
PrednisoneN/A1 trial
+1 more programs
Active Trials
NCT00418405Unknown1,500Est. Jan 2012
NCT01075711Completed2,728Est. Nov 2010
NCT01313858Completed1,613Est. Sep 2015
+4 more trials
I
IQVIANC - Durham
4 programs
4
GSK3196165Phase 31 trial
GSK3196165Phase 31 trial
GSK3196165Phase 31 trial
OtilimabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT03970837Terminated1,764Est. Jan 2023
NCT04134728Completed550Est. Feb 2022
NCT03980483Completed1,537Est. Aug 2022
+1 more trials
Amgen
AmgenTHOUSAND OAKS, CA
2 programs
2
ABP 501Phase 35 trials
ABP 710Phase 31 trial
Active Trials
NCT05073315Completed425Est. Dec 2022
NCT05909852Completed372Est. Nov 2021
NCT05995691Completed179Est. Dec 2015
+3 more trials
FUJIFILM Pharma
FUJIFILM PharmaMA - Cambridge
2 programs
2
FKB327Phase 31 trial
FKB327Phase 31 trial
Active Trials
NCT02260791CompletedEst. Jul 2016
NCT02405780CompletedEst. Jan 2018
UP
UCB PharmaBelgium - Brussels
1 program
1
CDP870Phase 31 trial
Active Trials
NCT00544154Completed247Est. Jan 2004
Takeda
TakedaTOKYO, Japan
2 programs
2
TAK-715 and methotrexatePhase 21 trial
TAK-783 and methotrexatePhase 21 trial
Active Trials
NCT00760864Completed432Est. Sep 2005
NCT00760968Completed224Est. Feb 2009
CSL Behring
CSL BehringIL - Bradley
1 program
1
ALD518Phase 21 trial
Active Trials
NCT00867516Completed127Est. Dec 2009
P
ParexelMA - Boston
1 program
1
GSK3196165Phase 21 trial
Active Trials
NCT02799472Completed39Est. Oct 2017
Kiniksa Pharmaceuticals
1 program
1
KPL-404Phase 21 trial
Active Trials
NCT05198310Completed145Est. May 2024
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
1
LY3009104Phase 21 trial
Active Trials
NCT01185353Completed301Est. Mar 2014
Astellas
AstellasChina - Shenyang
1 program
1
peficitinibPhase 2Small Molecule2 trials
Active Trials
NCT03971253Recruiting3,000Est. May 2026
NCT01711814Completed611Est. Mar 2016
E
EisaiChina - Liaoning
2 programs
1
E6011Phase 1/21 trial
Non-interventionalN/A1 trial
Active Trials
NCT06246123Recruiting2,040Est. Jul 2027
NCT02196558Completed53Est. Jul 2017
Bristol Myers Squibb
1 program
1
BMS-986528Phase 1/21 trial
Active Trials
NCT07412704Not Yet Recruiting84Est. Sep 2030
Biogen
BiogenCAMBRIDGE, MA
2 programs
Biomarkers of Anti-TNF-α Therapy Efficacy in Rheumatoid Arthritis to Define Unresponsive PatientsN/A1 trial
InfliximabN/AMonoclonal Antibody1 trial
Active Trials
NCT01211678Completed301Est. Jul 2013
NCT03662919Completed2,274Est. Jun 2022
J&
Johnson & JohnsonNEW BRUNSWICK, NJ
1 program
Total Knee System made in ChinaN/A1 trial
Active Trials
NCT02399046Completed160Est. Oct 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
RocheTocilizumab
SanofiLeflunomide
Pfizervaldecoxib
SanofiLEFLUNOMIDE
AmgenABP 501
IQVIAOtilimab
IQVIAGSK3196165
IQVIAGSK3196165
IQVIAGSK3196165
AmgenABP 710
Boehringer IngelheimBI 695501
FUJIFILM PharmaFKB327
Boehringer IngelheimBI 695501
FUJIFILM PharmaFKB327
AmgenABP 501

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 22,810 patients across 50 trials

NCT02087696RocheTocilizumab

Uncontrolled Study to Evaluate Efficacy of Tocilizumab in Patients With Moderate or Severe Rheumatoid Arthritis

Start: May 2014Est. completion: Jul 2016122 patients
Phase 4Unknown

Leflunomide in Rheumatoid Arthritis

Start: Apr 200460 patients
Phase 4Completed

Efficacy and Safety of Valdecoxib and Naproxen in Treating the Signs and Symptoms of Rheumatoid Arthritis (RA) in a Severe Rheumatoid Arthritis Patients

Start: Feb 2003Est. completion: Jan 2005489 patients
Phase 4Completed

Objective Study in Rheumatoid Arthritis

Start: Mar 2002249 patients
Phase 4Completed

A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis

Start: Oct 2021Est. completion: Dec 2022425 patients
Phase 3Completed

Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA)

Start: May 2020Est. completion: Feb 20232,916 patients
Phase 3Terminated

Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors

Start: Oct 2019Est. completion: Feb 2022550 patients
Phase 3Completed

Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)

Start: Jun 2019Est. completion: Jan 20231,764 patients
Phase 3Terminated

Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

Start: May 2019Est. completion: Aug 20221,537 patients
Phase 3Completed

Study to Assess if ABP710 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Infliximab

Start: Oct 2016Est. completion: Aug 2018558 patients
Phase 3Completed

Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis

Start: Jan 2016Est. completion: Nov 2017430 patients
Phase 3Completed

A Study to Compare FKB327 Long-term Safety, Efficacy and Immunogenicity With Humira® in Rheumatoid Arthritis Patients

Start: Jun 2015Est. completion: Jan 2018
Phase 3Completed

BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis

Start: Jan 2015Est. completion: Oct 2016645 patients
Phase 3Completed

A Study to Compare FKB327 Efficacy and Safety With Humira® in Rheumatoid Arthritis Patients

Start: Dec 2014Est. completion: Jul 2016
Phase 3Completed

Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis

Start: Apr 2014Est. completion: Apr 2016467 patients
Phase 3Completed

Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis

Start: Oct 2013Est. completion: Mar 2015350 patients
Phase 3Completed

Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis

Start: Oct 2013Est. completion: Nov 2014526 patients
Phase 3Completed

Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis

Start: May 2013Est. completion: Nov 201691 patients
Phase 3Terminated

Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis

Start: Sep 2012Est. completion: Oct 2016294 patients
Phase 3Terminated

Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)

Start: Sep 2009Est. completion: Feb 20123,366 patients
Phase 3Completed
NCT00732875Merck & Co.Infliximab + methotrexate

A Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Korean Patients With Active Rheumatoid Arthritis Despite Methorexate (Extension Part)(Study P05645)(COMPLETED)

Start: Aug 2006Est. completion: May 200892 patients
Phase 3Completed

COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis

Start: Jun 2005Est. completion: Sep 20062,208 patients
Phase 3Completed

A Study to Compare Meloxicam IM Once Daily Versus Meloxicam Orally Once Daily in Patients With Rheumatoid Arthritis

Start: Jul 2004Est. completion: Dec 2004150 patients
Phase 3Completed

Efficacy and Safety of CDP870 and Methotrexate Compared to Methotrexate Alone in Subjects With Rheumatoid Arthritis

Start: Oct 2002Est. completion: Jan 2004247 patients
Phase 3Completed

A Multi-Center Trial to Compare Three Doses of Meloxicam and Placebo in Patients With Rheumatoid Arthritis

Start: Jun 2002Est. completion: Jul 20031,000 patients
Phase 3Completed

Ramipril in Rheumatoid Arthritis

Start: Jun 2004Est. completion: Jul 200613 patients
Phase 2/3Completed

Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor

Start: Dec 2021Est. completion: May 2024145 patients
Phase 2Completed

Mechanistic Study of GSK3196165 Plus Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis

Start: Jun 2016Est. completion: Oct 201739 patients
Phase 2Completed
NCT02636907Boehringer IngelheimBI 695501 Autoinjector

Assessment of the Handling Experience With the BI 695501 Autoinjector in Patients With Rheumatoid Arthritis Followed by an Extension Phase Using BI 695501 Prefilled Syringe

Start: Jan 2016Est. completion: Jun 201777 patients
Phase 2Completed

A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study

Start: Sep 2012Est. completion: Mar 2016611 patients
Phase 2Completed

A Study in Participants With Rheumatoid Arthritis on Background Methotrexate Therapy

Start: Oct 2010Est. completion: Mar 2014301 patients
Phase 2Completed

Safety, Efficacy and Pharmacokinetics Study of ALD518 in Patients With Active Rheumatoid Arthritis

Start: Oct 2008Est. completion: Dec 2009127 patients
Phase 2Completed

Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis

Start: Mar 2008Est. completion: Oct 2012222 patients
Phase 2Terminated
NCT00760968TakedaTAK-783 and methotrexate

Efficacy and Safety of TAK-783 in Subjects With Rheumatoid Arthritis

Start: Aug 2007Est. completion: Feb 2009224 patients
Phase 2Completed

Maraviroc in Rheumatoid Arthritis

Start: Feb 2007Est. completion: Oct 2008128 patients
Phase 2Terminated

A Study To Investigate The Effect Of 28 Days Of Dosing With GW856553 On Patients With Rheumatoid Arthritis

Start: Oct 2006Est. completion: Jan 200857 patients
Phase 2Completed

Single Dose Study Of GW856553 On A Protein That Is An Indicator For Rheumatoid Arthritis (RA)

Start: Nov 2005Est. completion: Nov 200651 patients
Phase 2Completed

SB-681323 In Subjects With Rheumatoid Arthritis

Start: Nov 2005Est. completion: Oct 200678 patients
Phase 2Completed

Study Of 90mg Of GW274150 In Subjects Over 50 Years, Who Have Rheumatoid Arthritis (RA)

Start: Aug 2005Est. completion: Sep 20056 patients
Phase 2Completed
NCT00134693GSKPrednisolone

A Single Dose Of Compound SB-681323 Compared To Prednisolone On A Protein That Is an Indicator For Rheumatoid Arthritis

Start: Jun 2005Est. completion: Aug 200677 patients
Phase 2Completed

HuMax-CD20 in Active Rheumatoid Arthritis, Phase I/II

Start: Feb 2005Est. completion: Sep 2007201 patients
Phase 2Completed
NCT00379600GSKrosiglitazone XR

The Anti-Inflammatory And Metabolic Effects Of Rosiglitazone In Subjects With Rheumatoid Arthritis

Start: Nov 2004Est. completion: Dec 200696 patients
Phase 2Completed

12-Week No-Rofecoxib Plus Aspirin Endoscopy Study (0782-003)

Start: Aug 2004Est. completion: Nov 200449 patients
Phase 2Terminated
NCT00760864TakedaTAK-715 and methotrexate

Safety and Efficacy of TAK-715 in Subjects With Rheumatoid Arthritis

Start: Aug 2004Est. completion: Sep 2005432 patients
Phase 2Completed

MK0782 + Low-Dose Aspirin 7-Day Erosion Endoscopy Study (0782-001)

Start: Jun 2004Est. completion: Aug 2004462 patients
Phase 2Completed
NCT02214888Boehringer IngelheimBIRB 796 BS, low dose

Efficacy, Safety and Pharmacokinetics of BIRB 796 BS Tablets in Patients With Active Rheumatoid Arthritis

Start: May 2003170 patients
Phase 2Terminated

Efficacy and Safety of BIIL 284 BS in Adult Patients With Active Rheumatoid Arthritis

Start: May 2001404 patients
Phase 2Completed

Efficacy and Safety of Different Doses of BIRB 796 BS in Patients With Active Rheumatoid Arthritis

Start: May 2001167 patients
Phase 2Completed

A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis

Start: May 2026Est. completion: Sep 203084 patients
Phase 1/2Not Yet Recruiting

A Study of E6011 in Japanese Subjects With Rheumatoid Arthritis

Start: May 2014Est. completion: Jul 201753 patients
Phase 1/2Completed

Related Jobs in Immunology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

19 late-stage (Phase 3) programs — potential near-term approvals
22 companies competing in this space